Physician profile
Yu Liu
NPI 1043415706
$5,861.28
in general payments reported to CMS, 2019-2025
28 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $121 · 2021: $248 · 2022: $533 · 2023: $685 · 2024: $1,645 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,708.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $157.33 |
| Education | $102.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,997.63 | 2023-2025 | Apokyn, Apokyn, Gocovri |
| Abbvie INC. | $494.81 | 2022-2025 | |
| Lilly USA, LLC | $493.27 | 2019-2025 | Zepbound, Mounjaro |
| Eisai INC. | $346.97 | 2019-2024 | |
| Amgen INC. | $342.94 | 2019 | |
| Ucb, INC. | $316.43 | 2019-2024 | Briviact |
| Argenx US, INC. | $223.85 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $210.93 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $207.89 | 2024-2025 | Nuplazid |
| Neurelis, INC. | $160.30 | 2021 | |
| Harmony Biosciences LLC | $128.72 | 2025 | |
| Allergan, INC. | $124.99 | 2019 | |
| Emd Serono, INC. | $124.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $124.80 | 2025 | |
| Pfizer INC. | $104.17 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $102.85 | 2022 | |
| Sk Life Science, INC. | $55.65 | 2025 | |
| Lundbeck LLC | $48.95 | 2024 | Vyepti |
| Grifols USA, LLC | $47.36 | 2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $40.12 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $29.47 | 2025 | |
| Alnylam Pharmaceuticals INC. | $29.00 | 2024 | Onpattro |
| Neurocrine Biosciences, INC. | $19.28 | 2025 | |
| Abbott Laboratories | $18.65 | 2025 | Infinity |
| Genentech USA, INC. | $17.62 | 2025 | Ocrevus |
| Resmed Corp | $16.79 | 2023 | |
| Biogen, INC. | $16.72 | 2023 | Vumerity |
| Philips North America LLC | $16.13 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.